文献速递细菌感染、耐药与抗菌药物

新型抗生素对碳青霉烯耐药肠杆菌目细菌的接种效应评估

Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
PubMed 文献 · Clin Microbiol Infect · 2022-06-28

该体外研究评估了接种量对40株临床碳青霉烯酶-producing肠杆菌目细菌对头孢地尔及四种新型β-内酰胺/β-内酰胺酶抑制剂MIC的影响。常规接种量下耐药率从头孢地尔的15%到头孢洛扎-他唑巴坦的90%不等;高接种量下多种药物出现敏感向耐药转换,以头孢地尔和亚胺培南-瑞来巴坦受影响最明显,头孢他啶-阿维巴坦仅轻度受影响。

要点

  • 常规接种量下头孢地尔和美罗培南-伐硼巴坦对碳青霉烯酶-producing肠杆菌目细菌最有效。
  • 高接种量下头孢地尔敏感转耐药比例达88%(30/34),亚胺培南-瑞来巴坦为72%(13/18)。
  • 头孢他啶-阿维巴坦在高接种量下仅8.7%(2/23)发生敏感转耐药。

核心结论

  • 常规接种量下头孢地尔和美罗培南-伐硼巴坦对碳青霉烯酶-producing肠杆菌目细菌最有效。
  • 接种量增至10^7 CFU/mL时所有药物均受影响,头孢地尔和亚胺培南-瑞来巴坦尤为明显,头孢他啶-阿维巴坦仅轻度受影响。
  • 作者的体外结果有待体内证实。

研究设计与样本

  • 体外研究,纳入40株临床碳青霉烯酶-producing肠杆菌目细菌。
  • 在常规接种量(10^5 CFU/mL)和高接种量(10^7 CFU/mL)下测定头孢地尔及头孢洛扎-他唑巴坦、头孢他啶-阿维巴坦、亚胺培南-瑞来巴坦、美罗培南-伐硼巴坦的MIC。

主要发现

  • 常规接种量下耐药率:头孢地尔15%(n=6)、美罗培南-伐硼巴坦30%(n=12)、头孢他啶-阿维巴坦42.5%(n=17)、亚胺培南-瑞来巴坦55%(n=22)、头孢洛扎-他唑巴坦90%(n=36)。
  • 高接种量下敏感转耐药比例:头孢地尔88%(n=30/34;CI 71.6-96.2)、头孢洛扎-他唑巴坦75%(n=3/4;CI 21.9-98.7)、亚胺培南-瑞来巴坦72%(n=13/18;CI 46.4-89.3)、美罗培南-伐硼巴坦50%(n=14/28;CI 31.1-68.9)、头孢他啶-阿维巴坦8.7%(n=2/23;CI 1.5-29.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者的体外结果有待体内证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: New antibiotics have been developed to treat multidrug-resistant Enterobacterales. We evaluated the impact of the inoculum size on minimal inhibitory concentrations (MICs) of recently commercialized antibiotics. METHODS: We focused on 40 clinical carbapenemase-producing Enterobacterales and evaluated the impact of the inoculum size on the MICs to cefiderocol and to new β-lactams/β-lactamase inhibitors (ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam) at usual and high inocula (105 and 107 CFU/mL, respectively). RESULTS: At usual inoculum, 15% were resistant to cefiderocol (n = 6), 30% to meropenem-vaborbactam (n = 12), 42.5% to ceftazidime-avibactam (n = 17), 55% to imipenem-relebactam (n = 22), and 90% to ceftolozane-tazobactam (n = 36). At higher inoculum, a switch from susceptible to resistant category was observed for 88% (n = 30/34; CI, 71.6-96.2), 75% (n = 3/4; CI, 21.9-98.7), 72% (n = 13/18; CI, 46.4-89.3), 50% (n = 14/28; CI, 31.1-68.9), and 8.7% (n = 2/23; CI, 1.5-29.5) isolates regarding cefiderocol, ceftolozane-tazobactam, imipenem-relebactam, meropenem-vaborbactam, and ceftazidime-avibactam, respectively. DISCUSSION: Cefiderocol and meropenem-vaborbactam were the most efficient against carbapenemase-producing Enterobacterales at usual inoculum. When increasing inoculum to 107 CFU/mL, all of the molecules were impacted, particularly cefiderocol and imipenem-relebactam, while others, such as ceftazidime-avibactam, remain mildly affected. Our in vitro results deserved to be confirmed in vivo.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Danjean M, Hobson CA, Gits-Muselli M, et al. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. Clin Microbiol Infect. 2022. PMID: 35777602. doi:10.1016/j.cmi.2022.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。